{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:48:19Z","timestamp":1777420099973,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antiretroviral adherence is essential to achieve viral suppression and limit HIV-related morbidity and mortality; however, antiretroviral adherence thresholds to achieve viral suppression in clinical practice have not been fully characterized using administrative claims data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to assess the relationship between medication adherence and viral suppression among adult persons with HIV\/AIDS (PWH) receiving antiretroviral therapy (ART) for \u22656 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This historical cohort, real-world investigation assessed maintenance of viral load suppression and viral load area-under-the-curve (vAUC) in PWH \u226518 years of age based on ART adherence. A marginal effects model was used to determine the predicted probabilities of final plasma HIV-1 RNA &lt;50 copies\/mL or vAUC &lt;1,000 copy-days\/mL according to the medication possession ratio (MPR), estimated using a Jackknife model variance estimator and a delta-method for marginal effects standard error. Tests for statistical significance used a \u0160id\u00e1k method to correct for multiple comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean MPR for ART was 86.7% (95% CI: 85.0%\u201388.4%) for the 372 PWH included in the study. The marginal effects analysis indicated that an MPR \u226582% was associated with a predicted probability of viral suppression &lt;50 copies\/mL ( P &lt; 0.05). Significant predicted probabilities for vAUC &lt;1,000 copy-days\/mL were observed with an MPR \u226590% ( P &lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Medication possession ratio as a proxy for drug exposure was significantly and consistently associated with viral suppression using a longitudinal measure of HIV viremia. These findings can aid clinicians in the clinical management of PWH and inform future studies of adherence-viral suppression relationships with contemporary antiretroviral regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231156624","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T08:56:11Z","timestamp":1679475371000},"page":"1264-1272","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Medication Possession Ratio as a Predictor of Longitudinal HIV-1 Viral Suppression"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-1624","authenticated-orcid":false,"given":"R. Chris","family":"Rathbun","sequence":"first","affiliation":[{"name":"Department of Pharmacy: Clinical & Administrative Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0248-8113","authenticated-orcid":false,"given":"Wei Cheng","family":"Yuet","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukyung","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, The State University of New York, Buffalo, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2637-2550","authenticated-orcid":false,"given":"Jamie L.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy: Clinical & Administrative Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant H.","family":"Skrepnek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy: Clinical & Administrative Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"bibr1-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30066-8"},{"key":"bibr2-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61998-4"},{"key":"bibr3-10600280231156624","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. September 21, 2022. Department of Health and Human Services. Accessed December 7, 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"key":"bibr4-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2008.0141"},{"key":"bibr5-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/217047"},{"key":"bibr6-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(99)80026-5"},{"key":"bibr7-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H018"},{"key":"bibr8-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02898.x"},{"key":"bibr9-10600280231156624","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2006.12.3.239"},{"key":"bibr10-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq167"},{"key":"bibr11-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab392"},{"key":"bibr12-10600280231156624","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.10.1073"},{"key":"bibr13-10600280231156624","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"bibr14-10600280231156624","volume-title":"Econometric Analysis","author":"Greene WH","year":"2018","edition":"8"},{"issue":"318","key":"bibr15-10600280231156624","first-page":"626","volume":"62","author":"\u0160id\u00e1k ZK","year":"1967","journal-title":"J Am Stat Assoc"},{"key":"bibr16-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056307"},{"key":"bibr17-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinepi.2004.04.002"},{"key":"bibr18-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2010.0324"},{"key":"bibr19-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02744-w"},{"key":"bibr20-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00543.x"},{"key":"bibr21-10600280231156624","unstructured":"Pharmacy Quality Alliance. PQA quality measures: adherence. April 19, 2022. Accessed July 8, 2022. https:\/\/www.pqaalliance.org\/adherence-measures"},{"key":"bibr22-10600280231156624","unstructured":"Pharmacy Quality Alliance. PQA\u2019s specialty core measures set. February 4, 2021. Accessed July 8, 2022. https:\/\/www.pqaalliance.org\/assets\/Measures\/PQASpecialty_Measure_Core_Set.pdf"},{"key":"bibr23-10600280231156624","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002142"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231156624","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231156624","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231156624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:04Z","timestamp":1777374784000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231156624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1177\/10600280231156624"],"URL":"https:\/\/doi.org\/10.1177\/10600280231156624","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]}}}